{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:43:43Z","timestamp":1790160223111,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3174,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.bbmt.2006.03.012","type":"journal-article","created":{"date-parts":[[2006,7,24]],"date-time":"2006-07-24T09:10:12Z","timestamp":1153732212000},"page":"795-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Role of Allogeneic Stem Cell Transplantation for Adult Chronic Myeloid Leukemia in the Imatinib Era"],"prefix":"10.1016","volume":"12","author":[{"given":"Andrew","family":"Grigg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.03.012_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib2","first-page":"S89","article-title":"Long-term outcome after allogeneic stem cell transplantation for CML","volume":"5","author":"Goldman","year":"2004","journal-title":"Hematol J."},{"key":"10.1016\/j.bbmt.2006.03.012_bib3","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.V90.7.2549","article-title":"Use of \u03b1-2a-interferon to treated cytogenetic relapse of chronic myeloid leukemia after marrow transplantation","volume":"90","author":"Higano","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02075.x","article-title":"Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?","volume":"110","author":"Mackinnon","year":"2000","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib6","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bbmt.2006.03.012_bib7","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"23","author":"Hess","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib8","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia, comparative analysis of unrelated versus matched sibling donor transplantation","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib10","first-page":"263","article-title":"HLA matching and hematopoietic cell transplant outcome","author":"Mickelson","year":"2002","journal-title":"Clin Transpl."},{"key":"10.1016\/j.bbmt.2006.03.012_bib11","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2006.03.012_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.03.012_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib14","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood.V94.11.3960a","article-title":"Long term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia","volume":"44","author":"Clift","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V94.2.384","article-title":"The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow","volume":"94","author":"Elmaagacli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbmt.2004.09.010","article-title":"Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia","volume":"11","author":"Oehler","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2006.03.012_bib17","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies, an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1046\/j.1365-2141.2000.02053.x","article-title":"Quality of life in 244 recipients of allogeneic bone marrow transplantation","volume":"110","author":"Chiodi","year":"2000","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib19","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V100.12.3877","article-title":"Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft versus host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.leu.2403730","article-title":"Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML","volume":"19","author":"Kerbauy","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.bbmt.2006.03.012_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1704231","article-title":"The graft versus leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia","volume":"32","author":"Sloand","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2006.03.012_bib24","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib25","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood.V93.5.1534","article-title":"Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia","volume":"93","author":"Carella","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib26","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.10931","article-title":"Autologous stem cell transplantation for patients with chronic myeloid leukemia","volume":"95","author":"Koziner","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.leu.2402917","article-title":"Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR","volume":"17","author":"Hui","year":"2003","journal-title":"Leukemia."},{"key":"10.1016\/j.bbmt.2006.03.012_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V106.11.166.166","article-title":"Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM)","volume":"106","author":"Simonsson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V104.11.274.274","article-title":"BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V104.11.271.271","article-title":"The frequency of detection of BCR-ABL mutations in imatinib treated patients with chronic phase CML who attain a complete cytogenetic response (CCR) does not diminish with increasing duration of CCR but the associated loss of response is usually gradual","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib31","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V104.11.1001.1001","article-title":"Higher dose imatinib (600mg\/day) with selective intensification in newly diagnosed CML patient in chronic phase; cytogenetic response rates at 12 months are superior to IRIS","volume":"104","author":"Hughes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib33","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/cncr.20674","article-title":"Long term survival estimates for imatinib versus interferon-\u03b1 plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Anstrom","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib34","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.leu.2403752","article-title":"Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation","volume":"19","author":"Lange","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.bbmt.2006.03.012_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/1042819031000151905","article-title":"Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells","volume":"45","author":"Holtz","year":"2004","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.bbmt.2006.03.012_bib37","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/cncr.11729","article-title":"Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"98","author":"Medina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib38","first-page":"360","article-title":"Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib, is it under-reported and does it have any clinical significance?","volume":"127","author":"O\u2019Shea","year":"2004","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib39","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1182\/blood.V106.11.4862.4862","article-title":"Secondary leukemia after imatinib mesylate (IM) therapy for chronic myelogenous leukemia (CML)","volume":"106","author":"Kovitz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1704638","article-title":"A single centre assessment of long term quality of life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase","volume":"34","author":"Hayden","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2006.03.012_bib41","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1445-5994.2004.00757.x","article-title":"Corticosteroid-responsive interstitial pneumonitis related to imatinib mesylate with successful rechallenge, and potential causative mechanisms","volume":"35","author":"Grimison","year":"2005","journal-title":"Int Med J."},{"key":"10.1016\/j.bbmt.2006.03.012_bib43","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2002-12-3696","article-title":"Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia","volume":"101","author":"Sanchez-Gonzalez","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.bbmt.2006.03.012_bib45","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2003-07-2323","article-title":"Fatal hepatic necrosis following imatinib mesylate therapy","volume":"102","author":"Lin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2004.00347.x","article-title":"Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ajh.10186","article-title":"Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia","volume":"71","author":"Barton","year":"2002","journal-title":"Am J Hematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib48","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(02)08616-6","article-title":"Cerebral oedema as a possible complication of treatment with imatinib","volume":"359","author":"Ebnoether","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.03.012_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib50","first-page":"1089","article-title":"Reproductive status in long term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120mg\/kg)","volume":"6","author":"Grigg","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bbmt.2006.03.012_bib51","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2006.03.012_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/shem.2003.50038","article-title":"Imatinib treatment","volume":"40","author":"Hensley","year":"2003","journal-title":"Semin Hematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib53","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdj065","article-title":"Pregnancy on imatinib","volume":"17","author":"Choudhary","year":"2006","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib55","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2006.03.012_bib56","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bbmt.2006.03.012_bib57","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","article-title":"In-vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in de-novo CML patients","volume":"206","author":"White","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib58","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2002-09-2763","article-title":"Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib59","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.leu.2403570","article-title":"Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9","volume":"19","author":"Lundan","year":"2005","journal-title":"Leukemia."},{"key":"10.1016\/j.bbmt.2006.03.012_bib61","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation-2005.1.174","article-title":"Chronic myeloid leukaemia","author":"Deininger","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2006.03.012_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V104.11.21.21","article-title":"Sustained durability of response plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy","volume":"104","author":"Guilhot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib64","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib65","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.bbmt.2006.03.012_bib66","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib67","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V106.11.1086.1086","article-title":"Long term observation of CML patients after imatinib resistance associated with BCR-ABL mutations","volume":"106","author":"Hochhaus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gore","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2006.03.012_bib69","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.V106.11.1091.1091","article-title":"Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) which chronic myeloid leukemia (CML) treated at MD Anderson Cancer Center (MDACC)","volume":"106","author":"Jabbour","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib71","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib72","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib73","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2006.03.012_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V106.11.38.38","article-title":"Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (PH+ ALL) who are resistant or intolerant to imatinib","volume":"106","author":"Sawyers","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib75","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.V106.11.437.437","article-title":"Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients","volume":"106","author":"Branford","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib76","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood.V106.11.695.695","article-title":"Dasatinib (BMS-354825) has increased activity against bcr-abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells","volume":"106","author":"Copland","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood.V106.11.37.37","article-title":"AMN107, a novel aminopyrimidine inhibitor of bcr-abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome-positive acute lymphoid leukemia (Ph+ ALL)","volume":"106","author":"Kantarjian","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib78","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1182\/blood.V104.11.2752.2752","article-title":"A retrospective study of patients treated with imatinib mesylate prior to allogeneic hematopoietic stem cell transplant","volume":"104","author":"Oehler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib79","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival Benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-\u03b1","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(03)14182-7","article-title":"Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa","volume":"362","author":"Marin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2006.03.012_bib81","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood.V104.11.1996.1996","article-title":"Chronic myeloid leukemia stem cells and their differentiated progeny display divergent drug sensitivities to imatinib mesylate and interferon-alpha","volume":"104","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib82","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib83","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V98.10.2922","article-title":"Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia","volume":"98","author":"Petersdorf","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib84","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib85","first-page":"634","article-title":"Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase","volume":"102","author":"Druker","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib86","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib87","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.21032","article-title":"Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia \u2013 comparison with historic experience","volume":"103","author":"Kantarjian","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2006.03.012_bib88","first-page":"1928","article-title":"Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia","volume":"89","author":"Talpaz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib89","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O\u2019Dwyer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib90","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib91","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib92","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1046\/j.1365-2141.2000.02060.x","article-title":"Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia","volume":"109","author":"Visani","year":"2000","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2006.03.012_bib93","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.bbmt.2006.03.012_bib94","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood-2004-02-0508","article-title":"Risk factors for syngeneic graft versus host disease after adult hematopoietic cell transplantation","volume":"104","author":"Adams","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.03.012_bib95","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2403502","article-title":"Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome positive chronic myeloid leukemia","volume":"18","author":"Kim","year":"2004","journal-title":"Leukemia."},{"key":"10.1016\/j.bbmt.2006.03.012_bib96","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.V104.11.812.812","article-title":"Sequential treatment with reduced intensity allogeneic stem cell transplantation and imatinib for chronic myelogenous leukemia (CML)","volume":"104","author":"Champlin","year":"2004","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387910600293X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387910600293X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:26:05Z","timestamp":1761056765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387910600293X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S108387910600293X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.03.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Allogeneic Stem Cell Transplantation for Adult Chronic Myeloid Leukemia in the Imatinib Era","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}